Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Forms Division to Develop microRNA Disease Biomarkers

Premium

Regulus Therapeutics this week announced today that it has established a new research and development division that will focus on the identification of miRNAs as disease biomarkers.

Called Regulus microMarkers, the new unit will further develop Regulus' technology for extracting, profiling, and analyzing miRNAs, the company said.

“We believe that with our technical expertise and know-how, we can enhance early drug discovery and development processes by identifying microRNAs as biomarkers of disease and strengthening our therapeutic programs, and our collaborators’ and strategic partners’ programs," Regulus President and CEO Kleanthis Xanthopoulos said in a statement.

In 2012, Regulus partnered with Biogen Idec to discover miRNAs that could serve as biomarkers for multiple sclerosis. In November, Regulus announced that it had hit a key milestone in that alliance, profiling over 400 serum samples from MS patients and comparing them against samples from healthy volunteers.

Regulus also recently disclosed that it had struck a similar deal with an unnamed pharmaceutical firm for an undisclosed indication.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.